In summary, our findings confirm TIGIT together with PD-1 as a potential novel signature marker combination of dysfunctional HCV-specific CD4+ T cells and suggest that TIGIT along with other checkpoint receptors may be a curative target to reverse T cell exhaustion in chronic viral diseases or cancer. This evidence concerns the gene TIGIT and cancer.